Reviewed evidence dossier / BPC-01
BPC-157 evidence:
model first. Conclusion second.
The cited record is dominated by cell and animal research, with very limited human observations and unresolved safety questions. This dossier labels each model before describing a finding and does not convert preclinical signals into established human outcomes.
A preclinical research landscape.
The cited sources establish that BPC-157 has been investigated in defined cell systems, animal models, small human observations, and regulatory review materials.
Broad human repair or long-term safety.
The record does not establish treatment of injury or disease, uncommon harms, long-term safety, catalog-vial identity, or a product-specific use.
What kind of answer can this dossier provide?
BPC-157 is a synthetic 15-amino-acid research peptide. Much of the published outcome literature involves cell systems or animal injury models. Small or uncontrolled human observations do not resolve broad effectiveness, uncommon harms, pharmacokinetics, or long-term safety.
A reference sequence cannot verify a seller’s vial.
PubChem records BPC-157 under CID 9941957 with the sequence GEPPPGKPADDAGLV. That reference can help disambiguate the research identity. It does not establish the identity, purity, strength, stability, sterility, safety, or biological equivalence of any commercial material.
FDA’s July 2026 advisory briefing describes agency concerns and a proposal. It should not be described as a final prohibition or final 503A decision unless a later official record says so.
Finding, model, limitation, source.
HUMAN DATA
What has actually reached people?
FDA’s 2026 review describes meeting abstracts, small uncontrolled reports, a retrospective chart review, and tiny pilot studies. A separate 2025 report describes measurements in two previously exposed participants.
Limit: These observations cannot establish population safety, effectiveness, pharmacokinetics, uncommon harms, or broad generalizability.
MODELS
Gastrointestinal injury and repair models
Rat studies report observations in gastrointestinal injury, anastomosis, fistula, and ulcer models.
Limit: Those experiments do not establish healing of ulcers, restoration of a human intestinal barrier, or outcomes in unrelated tissues.
REVIEW
Musculoskeletal evidence remains predominantly preclinical
A 2025 sports-medicine systematic review mapped the musculoskeletal literature and identified the dominance of preclinical evidence.
Limit: A literature signal in animal or laboratory models does not establish a broad human repair outcome.
MODEL
Neurological injury experiments
Rat experiments have examined spinal-cord, peripheral-nerve, and brain-injury models.
Limit: The cited record does not establish axon regeneration, traumatic-brain-injury recovery, neurological treatment, or age-related neuroprotection in people.
ANIMAL
Vascular and nitric-oxide hypotheses
Angiogenesis, endothelial, and nitric-oxide pathways have been explored in cell systems and animals.
Limit: A proposed pathway does not establish changes in circulation, blood pressure, heart tissue, nutrient delivery, or systemic inflammation in people.
ASSESSMENT
Identity, quality, immunogenicity, and safety gaps
FDA materials identify potential immunogenicity, impurity, active-ingredient characterization, safety, and effectiveness concerns.
Limit: The July 2026 advisory materials document an assessment and proposal; they are not themselves a final prohibition or a quantified incidence of risk.
Questions the cited record does not resolve.
The record lacks adequate controlled human research to establish broad injury, gastrointestinal, neurological, vascular, or inflammatory outcomes.
Tiny or uncontrolled observations do not resolve population pharmacokinetics, exposure-response, or generalizability.
The available record cannot resolve uncommon harms, immunogenicity, or long-term safety.
A name or reference sequence does not establish identity, purity, strength, safety, efficacy, approval, or intended use for a seller’s material.
Model first. Conclusion second.
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid research peptide. Exact identity and experimental context matter when comparing a catalog name with a published record.
How much human evidence is represented in the cited record?
FDA’s 2026 review describes meeting abstracts, small uncontrolled reports, a retrospective chart review, and tiny pilot studies. A 2025 report describes two previously exposed participants. That record is too limited to resolve broad outcomes, uncommon harms, pharmacokinetics, or long-term safety.
Where does most published outcome evidence come from?
Much of the cited record comes from cell systems and animal models. Those experiments identify research questions; they do not establish corresponding outcomes in people.
Does the musculoskeletal literature establish a broad human repair outcome?
No. The cited 2025 systematic review describes an evidence base that is predominantly preclinical.
Has FDA identified unresolved safety questions?
Yes. FDA materials identify potential immunogenicity, impurity, active-ingredient characterization, safety, and effectiveness gaps. The July 2026 advisory material describes an agency proposal, not a final prohibition or final 503A decision.
Is lack of patentability a supported explanation for the state of the evidence?
No. A 2025 literature and patent review identifies BPC-157 patent applications and granted patents. The defensible evidence gap is insufficient controlled human research and unresolved safety—not a claimed absence of patentability.
Does this dossier evaluate any PSC catalog vial?
No. A reference identity or published study does not establish the identity, purity, strength, safety, efficacy, approval, or intended use of a seller’s material.
Open the model and the limitation together.
- FDA Pharmacy Compounding Advisory Committee briefing · July 2026Agency assessment of identity, nonclinical and human evidence, pharmacology, quality, safety gaps, and a proposed recommendation. Not a final prohibition.FDA briefing PDF ↗
- FDA compounding safety-risk summaryLive agency page describing potential immunogenicity, impurity, characterization, and human-data concerns.FDA record ↗
- Two-person human observation · 2025Reported measurements and short observation period in two previously exposed participants; cannot establish population outcomes.PubMed 40131143 ↗
- Vasireddi et al. · HSS Journal · 2025Systematic review of the musculoskeletal literature and its predominantly preclinical evidence base.Publisher PDF ↗
- Vuksic et al. · Surgery Today · 2007Ileoileal anastomosis experiment in rats; representative gastrointestinal model.PubMed 17713731 ↗
- Perovic et al. · Journal of Orthopaedic Research · 2019Spinal-cord injury experiment in rats; not human neurological evidence.PubMed 31266512 ↗
- Józwiak et al. · Pharmaceuticals · 2025Literature and patent review covering preclinical scope, insufficient clinical studies, applications, and granted patents.PubMed 40005999 ↗
Versioned, not silently rewritten.
Version 1.0 published. Added model-labeled findings, factual FAQs, PubChem identity boundary, and an explicit distinction between FDA’s July 2026 proposal and a final regulatory decision.
A substantive correction records the date, changed statement, reason, and supporting source. Send a precise citation or correction request through the PSC policies and contact page.